- Home
- LPRO vs CERS Comparison
LPRO vs CERS Comparison
Compare LPRO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- CERS
- Stock Information
- Founded
- LPRO 2000
- CERS 1991
- Country
- LPRO United States
- CERS United States
- Employees
- LPRO N/A
- CERS N/A
- Industry
- LPRO Finance: Consumer Services
- CERS EDP Services
- Sector
- LPRO Finance
- CERS Technology
- Exchange
- LPRO Nasdaq
- CERS Nasdaq
- Market Cap
- LPRO 252.9M
- CERS 276.0M
- IPO Year
- LPRO N/A
- CERS 1997
- Fundamental
- Price
- LPRO $1.80
- CERS $1.51
- Analyst Decision
- LPRO Buy
- CERS Strong Buy
- Analyst Count
- LPRO 6
- CERS 2
- Target Price
- LPRO $3.00
- CERS $3.50
- AVG Volume (30 Days)
- LPRO 660.9K
- CERS 1.2M
- Earning Date
- LPRO 11-06-2025
- CERS 11-06-2025
- Dividend Yield
- LPRO N/A
- CERS N/A
- EPS Growth
- LPRO N/A
- CERS N/A
- EPS
- LPRO N/A
- CERS N/A
- Revenue
- LPRO $16,254,999.00
- CERS $192,510,000.00
- Revenue This Year
- LPRO $306.78
- CERS $19.07
- Revenue Next Year
- LPRO $11.69
- CERS $12.03
- P/E Ratio
- LPRO N/A
- CERS N/A
- Revenue Growth
- LPRO N/A
- CERS 13.25
- 52 Week Low
- LPRO $0.70
- CERS $1.12
- 52 Week High
- LPRO $6.92
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- LPRO 39.97
- CERS 49.09
- Support Level
- LPRO $1.78
- CERS $1.48
- Resistance Level
- LPRO $1.98
- CERS $1.55
- Average True Range (ATR)
- LPRO 0.13
- CERS 0.08
- MACD
- LPRO -0.01
- CERS -0.02
- Stochastic Oscillator
- LPRO 15.28
- CERS 15.00
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.